Trial Profile
Protocol AMT110-CD-001: A Phase I/II, Open-label, Study of Intracerebral Administration of Adeno-associated Viral Vector Containing the Human Alpha-N-acetylglucosaminidase cDNA in Children With Sanfilippo Type B Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs AMT 110 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions
- Sponsors uniQure
- 28 Nov 2019 Status changed from active, no longer recruiting to completed.
- 09 Oct 2017 New trial record